Role of EGFR mutation status in patients with advanced lung adenocarcinoma treated with pemetrexed
10.3969/j.issn.1000-8179.20131442
- VernacularTitle:晚期肺腺癌EGFR突变状态对培美曲塞疗效的影响
- Author:
Qiong ZHANG
;
Zhe YANG
;
Honghai DAI
;
Yu WANG
;
Junqing HAN
- Publication Type:Journal Article
- Keywords:
pulmonary adenocarcinoma;
pemetrexed;
chemotherapy;
epidermal growth factor receptor
- From:
Chinese Journal of Clinical Oncology
2013;(22):1378-1381
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the role of EGFR mutations on pemetrexed response in patients with advanced lung adenocarcino-ma. Method: Forty pulmonary adenocarcinoma patients with evaluable lesions were retrospectively screened .They had been treated with pemetrexed-included chemotherapy and had EGFR gene test results. The evaluation endpoints were overall response rate,disease control rate and progression free survival. Result:No significant statistical difference was seen in overall response rate(ORR) (44.4%VS 31.8%, respectively) and disease control rate(DCR) (88.9%VS 81.8%, respectively ) between EGFR wild group and EGFR muta-tion group, but patients in EGFR wild group had longer progression free survival(PFS) ( 8.9 months VS 5.3 months;P=0.046). Conclu-sion:EGFR mutation status can influence the efficacy of pemetrexed.
